PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27663589-0	2017	BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.	enzalutamide	51-63	baculoviral IAP repeat containing 6	Homo sapiens	0-5	
27663589-8	2017	Molecular pathways associated with growth inhibition were assessed via gene enrichment analysis.Results: Of eight IAPs examined, BIRC6 was the only one showing elevated expression in both enzalutamide-resistant CRPC models.	enzalutamide	188-200	baculoviral IAP repeat containing 6	Homo sapiens	129-134	
27663589-11	2017	Furthermore, ASO-6w2 inhibited expression of prosurvival genes that were upregulated in the LTL-313BR line.Conclusions:BIRC6 targeting inhibited the growth of enzalutamide-resistant CRPC models and may represent a new option for clinical treatment of advanced, enzalutamide-resistant prostate cancer.	enzalutamide	159-171	baculoviral IAP repeat containing 6	Homo sapiens	119-124	
27663589-11	2017	Furthermore, ASO-6w2 inhibited expression of prosurvival genes that were upregulated in the LTL-313BR line.Conclusions:BIRC6 targeting inhibited the growth of enzalutamide-resistant CRPC models and may represent a new option for clinical treatment of advanced, enzalutamide-resistant prostate cancer.	enzalutamide	261-273	baculoviral IAP repeat containing 6	Homo sapiens	119-124